Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TCM Biotech InternationalTPE:4169 -2.48%52 Gross Margin % is 44.65% as of Mar. 2026, which is 8% below its 10-year median of 48.66. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.31 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 735 Biotechnology companies, TCM Biotech International ranks worse than 64.49% on this metric.
TCM Biotech International (TPE:4169) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
TCM Biotech International had a gross margin of 44.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
TCM Biotech International Gross Margin % Related Terms
TCM Biotech International Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4169 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, TCM Biotech International's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's Gross Margin % distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
TCM Biotech International (TPE:4169) has a Gross Margin % of 44.65% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on TCM Biotech International and its competitors. This is near median its historical median of 48.66. Over the past decade, TCM Biotech International's Gross Margin % has ranged from 40.64 to 55.89. According to the industry distribution chart, TCM Biotech International ranks #474 out of 735 companies in the Biotechnology industry, placing it in the top 64.5%.
Is TCM Biotech International's Gross Margin % too high?
TCM Biotech International's current Gross Margin % of 44.65% is near median its 10-year median of 48.66. Over the past 10 years, this metric has ranged from a low of 40.64 to a high of 55.89. The Biotechnology industry median Gross Margin % is 60.69. TCM Biotech International's value of 44.65% is 26.4% below this industry median. Based on the distribution chart, TCM Biotech International ranks #474 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #474 out of 735 companies for Gross Margin %. This places TCM Biotech International in the lower half of its industry. The industry median Gross Margin % is 60.69. TCM Biotech International's value of 44.65% is 26.4% below this benchmark. Historically, TCM Biotech International's own Gross Margin % has ranged from 40.64 to 55.89 over the past decade. While the company's 10-year median is 48.66 vs. the industry median of 60.69, TCM Biotech International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.69, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TCM Biotech International's current Gross Margin % of 44.65% is 26.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on TCM Biotech International and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current Gross Margin % is 44.65%, which is near median its own 10-year median of 48.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current Gross Margin % is 44.65%, which is near median its 10-year median of 48.66 and 26.4% below the Biotechnology industry median of 60.69. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current Gross Margin % is 44.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
Gross Margin %: 44.65% (near median its 10-year median of 48.66)
GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
Industry Position: 26.4% below the Biotechnology median (#474 of 735)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
